Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.53 |
| ▸ | S100A10 | P60903 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 12/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 12/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466457 | 0.93 | TP53 (0.51) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL466453 | 0.86 | TP53 (0.48) | RXFP1TP53MDM2TSHR | |
| SCHEMBL5061944 | 0.85 | TP53 (0.50) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL5061950 | 0.85 | TP53 (0.50) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL466521 | 0.83 | TP53 (0.50) | TP53MDM2TSHR | |
| SCHEMBL5061982 | 0.83 | RXFP1 (0.52) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL5061975 | 0.83 | RXFP1 (0.52) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL14076329 | 0.83 | RXFP1 (0.52) | RXFP1ANXA2S100A10TP53MDM2 | |
| SCHEMBL466462 | 0.82 | FPR1 (0.59) | TP53MDM2KDM4E | |
| SCHEMBL14076307 | 0.81 | RXFP1 (0.48) | RXFP1ANXA2S100A10TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | claimed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | claimed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | claimed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | claimed |
| EP-2344157-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2011-07-20 | — | — | EP | claimed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | claimed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | claimed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2344157-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026212-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026209-A1 | Use of isoQC inhibitors | PROBIODRUG AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | RXFP1 176/4885ANXA2 4760/4885S100A10 4019/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | RXFP1 3103/4885ANXA2 4536/4885S100A10 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.